Omalizumab as add-on therapy to inhaled steroids for asthma.
Hadj Tahar
A
A
D000293:Adolescent; D000328:Adult; D018926:Anti-Allergic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000276:immunology; D001315:Australia; D002170:Canada; D002648:Child; D002986:Clinical Trials as Topic; D003365:Costs and Cost Analysis; D017277:Drug Approval; D006801:Humans; D006854:Hydrocortisone / Q000627:therapeutic use; D007073:Immunoglobulin E / Q000097:blood / Q000276:immunology*; D012449:Safety; D016896:Treatment Outcome; D014481:United States
D018926:Anti-Allergic Agents; D018927:Anti-Asthmatic Agents; D000911:Antibodies, Monoclonal; D007073:Immunoglobulin E; D006854:Hydrocortisone